Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 121 to 130 of 220 total matches.

In Brief: Asparaginase Erwinia chrysanthemi (Erwinaze) for ALL

   
The Medical Letter on Drugs and Therapeutics • Apr 16, 2012  (Issue 1388)
of childhood. Multidrug chemotherapy can cure about 80% of children with ALL.1 Initial treatment (“induction ...
The FDA has approved asparaginase Erwinia chrysanthemi (Erwinaze – EUSA), an asparagine-specific enzyme derived from the gram-negative bacillus Erwinia chrysanthemi, for use in combination with other chemotherapeutic agents for treatment of acute lymphoblastic leukemia (ALL) in patients who have had allergic reactions to Escherichia coli-derived asparaginase (Elspar or pegaspargase [Oncaspar]).ALL is the most common malignancy of childhood. Multidrug chemotherapy can cure about 80% of children with ALL.1 Initial treatment ("induction") usually includes vincristine, a glucocorticoid, and an...
Med Lett Drugs Ther. 2012 Apr 16;54(1388):32 |  Show IntroductionHide Introduction

Two New Drugs for Colon Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004  (Issue 1184)
colorectal cancer that had progressed despite treatment with an irinotecanbased chemotherapy regimen were ...
Cetuximab (Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab (Avastin - Genentech), the first vascular endothelial growth factor angiogenesis inhibitor, have recently been approved by the FDA for treatment of patients with metastatic colorectal cancer. Cetuximab is approved for treatment of patients with EGFR-expressing tumors, either in combination regimens with irinotecan (Camptosar)when the cancer has progressed on irinotecan-based therapy, or as monotherapy for those who cannot tolerate irinotecan. Bevacizumab is approved...
Med Lett Drugs Ther. 2004 Jun 7;46(1184):46-8 |  Show IntroductionHide Introduction

Acupuncture

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
Palliative Care – In one meta-analysis, acupuncture, particularly electroacupuncture, reduced chemotherapy ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Med Lett Drugs Ther. 2006 May 8;48(1234):38-9 |  Show IntroductionHide Introduction

Toremifene and Letrozole for Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 10, 1998  (Issue 1024)
OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS Cancer chemotherapy letrozole for breast ...
The antiestrogen toremifene (Fareston - Schering) and the selective aromatase inhibitor letrozole (Femara - Novartis) have been approved by the FDA for treatment of advanced breast cancer in postmenopausal women.
Med Lett Drugs Ther. 1998 Apr 10;40(1024):43-4 |  Show IntroductionHide Introduction

Two Drugs for RET-Altered Cancers (Retevmo and Gavreto) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
chemotherapy. The median duration of response was not yet reached in treatment-naive patients and 17.5 months ...
The oral kinase inhibitors selpercatinib (Retevmo – Lilly) and pralsetinib (Gavreto – Blueprint Medicines/Genentech) have been approved by the FDA for treatment of advanced or metastatic RET-mutant or RET fusion-positive cancers. They are the first drugs to be approved specifically for certain RET-driven cancers. Both drugs were granted accelerated approval based on overall response rates and the duration of response.
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e120-1   doi:10.58347/tml.2023.1680e |  Show IntroductionHide Introduction

Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
of platinum-based chemotherapy and/ or immunotherapy, but not tyrosine kinase inhibitor therapy, the overall ...
The FDA has approved the oral tyrosine kinase inhibitor repotrectinib (Augtyro – BMS) for treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults. Repotrectinib is the third oral tyrosine kinase inhibitor to be approved for this indication in the US; crizotinib (Xalkori) and entrectinib (Rozlytrek) were approved earlier.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e36-7   doi:10.58347/tml.2024.1696g |  Show IntroductionHide Introduction

In Brief: Dinutuximab (Unituxin) for High-Risk Neuroblastoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016  (Issue 1491)
that had at least a partial response to induction chemotherapy, autologous stem cell transplantation ...
The FDA has approved use of dinutuximab (Unituxin [yoo ni tux' in] – United Therapeutics) in combination with interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), and isotretinoin for treatment of children with high-risk neuroblastoma who previously responded to first-line therapies. Dinutuximab is a monoclonal antibody that binds to GD2, a glycolipid that is overexpressed on the surface of neuroblastoma cells.1Dinutuximab received a priority review and orphan drug designation. Approval was based on the results of an open-label trial in 226 patients with high-risk...
Med Lett Drugs Ther. 2016 Mar 28;58(1491):e48 |  Show IntroductionHide Introduction

Mitomycin Solution (Mitosol) for Glaucoma Surgery

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2013  (Issue 1412)
for reconstitution, sponges, a chemotherapy waste bag and instructions for use. One kit costs $359.3 CONCLUSION ...
A topical formulation of the antimetabolite mitomycin (Mitosol – Mobius Therapeutics) has been approved by the FDA for adjunctive use in glaucoma surgery to reduce scarring. Compounding pharmacies have supplied the drug off-label for this purpose for many years.
Med Lett Drugs Ther. 2013 Mar 18;55(1412):24 |  Show IntroductionHide Introduction

Mitoxantrone

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 1988  (Issue 769)
, with or without previous chemotherapy, with 35% to 57% response rates reported, similar to rates with combination ...
Mitoxantrone (Novantrone - Lederle), a synthetic anthracene related to the anthracyclines doxorubicin (Adriamycin) and daunorubicin (Cerubidine), has now been marketed in the USA to be used in combination with other drugs for initial treatment of acute nonlymphocytic leukemia in adults.
Med Lett Drugs Ther. 1988 Jul 1;30(769):67-8 |  Show IntroductionHide Introduction

Doripenem (Doribax) - A New Parenteral Carbapenem

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008  (Issue 1278)
. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September ...
Doripenem (Doribax - Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of complicated intra-abdominal and urinary tract infections. Use of doripenem for treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is still under FDA review.
Med Lett Drugs Ther. 2008 Jan 28;50(1278):5-7 |  Show IntroductionHide Introduction